Yale Cancer Center
@YaleCancer
Followers
17K
Following
9K
Media
4K
Statuses
9K
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.
New Haven, Connecticut
Joined September 2012
.@ranjitbindra joins @DrEricWiner tonight on #YaleCancerAnswers to discuss breakthroughs in #braincancer, new + promising treatments, and exciting work happening in the Bindra Lab. ▪️Listen live @wnpr.▪️Download @ApplePodcasts.▪️Watch @YouTube.@SmilowCancer @YNHH
0
0
4
Research led by @m_y_mayday uncovered how a mutant protein drives rare childhood leukemia #AMKL by hijacking RNA + Wnt signaling. Targeting these pathways with experimental inhibitors suppressed #leukemia growth. @BloodPortfolio @Krauselab_Yale
0
3
10
Rhabdomyosarcoma #RMS remains hard to treat, but new research from Yale shows NAPRT-silenced tumors are highly vulnerable to NAMPT inhibition-supporting biomarker-driven trials in pediatric RMS. @SmilowCancer @yalepathology @YaleRadOnc @YalePediatrics.
biorxiv.org
Purpose New treatments are needed to improve survival in children with rhabdomyosarcoma (RMS). NAD⁺ biosynthesis, regulated by the enzymes NAPRT and NAMPT, represents a metabolic vulnerability due to...
0
4
5
.@Dr_AmerZeidan et al. explain how #MDS disproportionately affects older adults, with treatment burden impacting outcomes. Oral HMA therapy- DEC-C, may improve persistence, clinical outcomes, + QOL while ⬇️ healthcare costs. @SmilowCancer @tandfonline.
tandfonline.com
Myelodysplastic syndromes/neoplasms (MDS) are a heterogenous group of myeloid cancers that impose a substantial negative impact on patient health-related quality of life. As MDS predominately affec...
2
1
6
#SCLC remains aggressive, but advances in chemoimmunotherapy + novel agents are ⬆️ survival. Early-stage SCLC now sees nearly 2-year OS gains with chemoradiation + immunotherapy. Unmet need remains for many pts. @SmilowCancer @Annechiangmd @ynie_md
0
1
2
A @ysphbiostat study led by @JeffTownsend reveals #tobacco alters lung #adenocarcinoma evolution: smokers’ tumors favor KRAS/KEAP1/STK11, never-smokers’ favor EGFR/PIK3CA—revealing distinct treatment vulnerabilities. @SmilowCancer @TooMuchVitaminK.
biorxiv.org
Background Tobacco smoke is a known mutagen. However, its physiological effects on the lung may also influence the somatic selective pressures acting on mutations, further shaping cancer evolution....
0
3
3
A new study provides analysis of the rare, aggressive lung cancer #LCNEC + finds current therapies limited. Results identify potential new targets + the need for personalized trials to improve care. .@SmilowCancer @NatureComms @AminNassarMD @Annechiangmd
0
0
0
RT @SmilowCancer: Drs. David Rimm @yalepathology + @tznaung found that #AI is more precise in predicting the likelihood of #melanoma recurr….
nbcconnecticut.com
The Yale School of Medicine is trying to figure out if artificial intelligence can help people with cancer. They, along with other researchers, found AI-based scoring of melanoma tumor-infiltrating...
0
3
0
#Prostatecancer rates are ⬆️ in the US as mortality plateaus. The @AmericanCancer Roundtable set 3 priorities: better screening, optimized localized care + stronger treatment for advanced disease. @SmilowCancer @WilliamOhMD @JournalCancer.
acsjournals.onlinelibrary.wiley.com
The American Cancer Society (ACS) engaged experts from across the prostate cancer continuum to identify key strategic priorities for public health intervention efforts. This ACS Prostate Cancer...
0
0
0
Can #cancer be prevented? Dr. Melinda Irwin @YaleSPH and @DrEricWiner discuss #cancerriskfactors- weight, obesity, tobacco, + alcohol, tonight at 7:30pm on #YaleCancerAnswers. 🎧 Listen live @wnpr.🔁 Download @ApplePodcasts.💻 Watch @YouTube.@SmilowCancer
1
0
5
A new @YaleRadiology study introduces 2 deep learning models that ⬆️ accuracy + standardization of #brachytherapy planning for #cervicalcancer, enabling precise dose prediction + safer treatment. @SmilowCancer.
pubmed.ncbi.nlm.nih.gov
Cervical cancer is a significant global health issue, and high-dose-rate brachytherapy (HDR-BT) is crucial for its treatment. However, manually creating HDR-BT plans is time-consuming and heavily...
0
0
0
New @jclinicalinvest study identifies TET3-overexpressing macrophages as a common driver of chronic inflammation in #MASH, #NSCLC + #endometriosis. Targeting TET3 in mice depleted these cells + slowed disease. .@SmilowCancer
1
4
6
A new @NatureGenet study from @MuzumdarLab + @SStevenWang reveals 3D genome maps in KRAS-driven lung & pancreatic #cancer, uncovering stage-specific changes and potential biomarkers of progression. #lungcancer #pancreaticcancer.➡️.@SmilowCancer
0
5
9
In metastatic #breastcancer, sacituzumab govitecan given after trastuzumab deruxtecan was linked to ⬇️ PFS across all subtypes. Real-world data published in @JNCI_Now show differences in outcomes by type. .@SmilowCancer @YaleBreast @maryam_lustberg.
academic.oup.com
AbstractBackground. Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available
0
8
13
RT @MuzumdarLab: Excited to share our latest paper in @NatureGenet with @SStevenWang on the evolution of 3D genome organization in 🐁 models….
nature.com
Nature Genetics - This study uses chromatin tracing to identify alterations in single-cell 3D genome conformation during the progression of Kras-driven mouse lung adenocarcinoma and pancreatic...
0
29
0
Congratulations to Jiangbing Zhou, PhD, named the Nixdorff-German Professor of Neurosurgery. Dr. Zhou is a pioneer in developing STEP technology, which could revolutionize #genomeediting. @SmilowCancer @YNeurosurgery
0
0
3
.@hthrparsons, medical oncologist + researcher @fredhutch, joins @DrEricWiner on #YaleCancerAnswers to discuss #liquidbiopsies, an emerging technology used in #cancerresearch + clinical practice. 🔹Listen live @wnpr.🔹Download @ApplePodcasts.🔹Watch @YouTube.@SmilowCancer
0
0
10
RT @YaleCSEI: @YaleCSEI and @YaleCancer were honored to co-host Jon Cohen (VP) and Laksshman Sundaram (Sr Mgr) from Applied Research at NV….
0
1
0